Elite Pharmaceuticals Inc (ELTP)

[WeeZuhl]

You are correct, Doctor, but miss the point.

As you know, the half life of naloxone or naltrexone is largely irrelevant as these substances only come into play when abuse is undertaken and then the half life of such is not the same as the GI half life of the drugs if taken via oral administration. Further, as you know, in the case of Targiniq, the bioavailability after oral administration of noloxone is negligible, ie less than 2% by design.

While you are correct to say that naloxone oral availability is negligible by design, you miss my point that Targiniq is a lame ADF. It is apparently given ADF label because of the presence of naloxone to block euphoria when crushed for snorting and injection. But the half-life of naloxone is so short and the dose is so miniscule, the euphoria-blocking effect for tampered doses is nil, as is clearly seen in the Targiniq Mean Drug Liking graph below:


http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205777Orig1s000ClinPharmR.pdf








See that? Targiniq drug-liking for chewed sample (blue line) is essentially the exact same as straight oxy (green line). ZERO abuse deterrence. None at all! And for review, compare this graph to a true antagonist ADF, which shows complete euphoria-blocking AND aversive disliking properties:











The evidence is very clear here. As far as abuse deterrence is concerned, ELTP 2 bead pharma-based ADF is FAR SUPERIOR to the "ADF" technology in Targiniq.